Best’s Market Segment Report: Taiwan’s Non-Life Insurance Premiums Continue to Increase Amid Underwriting Improvements
HONG KONG–(BUSINESS WIRE)–#insurance–Taiwan’s domestic non-life insurance premium continued to increase in 2024, growing 10.5% to reach TWD 278.5... Read more.
Both ISS and Glass Lewis Recommend Shareholders Vote AGAINST Keisei President Toshiya Kobayashi, Endorsing Palliser’s Call for Governance Reform
Unanimous ISS and Glass Lewis recommendation to vote AGAINST current President Kobayashi to hold him accountable for severe long-standing failures in governance... Read more.
Resecurity Expands LATAM Presence Through Strategic Partnership with INFORC in Ecuador
LOS ANGELES & QUITO, Ecuador–(BUSINESS WIRE)–Resecurity, a U.S.-based cybersecurity and threat intelligence company, is pleased to announce a new... Read more.
NPWR Deadline: Rosen Law Firm Urges NET Power, Inc. (NYSE: NPWR) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
NEW YORK–(BUSINESS WIRE)–Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers... Read more.
Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)
Results from the EPCORE® NHL-2 trial show investigational treatment with epcoritamab in combination with rituximab, ifosfamide, carboplatin, and etoposide (R-ICE)... Read more.
QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)
QIAGEN to create a multimodal panel using next-generation sequencing (NGS) technology for detecting clinically relevant gene alterations in hematological malignancies... Read more.
Positive Late-Breaking Data for Incyte’s First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025
Data demonstrates the potential for INCA033989 to modify disease by directly inhibiting and eliminating oncogenic mutCALR cells, while sparing healthy cells and... Read more.
Sarepta Provides Safety Update for ELEVIDYS and Initiates Steps to Strengthen Safety in Non-Ambulatory Individuals with Duchenne
– The Company is developing an enhanced immunosuppressive regimen in consultation with a panel of multi-disciplinary clinical experts and engaging with regulators... Read more.
FinTech Leader Kennel Connection Launches Enhanced Report Cards to Help Pet Care Pros Save Time and Build Trust
MOORPARK, Calif.–(BUSINESS WIRE)–Kennel Connection, a leader in pet care management software and a 100GROUP company, is proud to announce a comprehensive... Read more.
RCKT INVESTOR ALERT: Robbins Geller Rudman & Dowd Announces that Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
SAN DIEGO–(BUSINESS WIRE)–The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Rocket Pharmaceuticals, Inc.... Read more.